Following neurotrauma, secondary degeneration of neurons and glia adjacent to the injury leads to further functional loss. A combination of ion channel inhibitors (lomerizine + oxATP + YM872) has been shown to be effective at limiting structural and functional loss due to secondary degeneration. Here we assess efficacy of the combination where oxATP is replaced with Brilliant Blue G (BBG), a more clinically applicable P2X 7 receptor inhibitor. Partial optic nerve transection was used to model secondary degeneration in adult female rats. Animals were treated with combinations of lomerizine + YM872 + oxATP or lomerizine + YM872 + BBG, delivered via osmotic mini-pump directly to the injury site. Outcomes assessed were Iba1 + and ED1 + microglia and macrophages, oligodendroglial cell numbers, node/paranode structure and visual function using the optokinetic nystagmus test. The lomerizine + BBG + YM872 combination was at least as effective at the tested concentrations as the lomerizine + oxATP + YM872 combination at preserving node/paranode structure and visual function when delivered locally. However, neither ion channel inhibitor combination significantly improved microglial/macrophage nor oligodendroglial numbers compared to vehicle-treated controls. In conclusion, a locally delivered combination of ion channel inhibitors incorporating lomerizine + BBG + YM872 is at least as effective at limiting secondary degeneration following partial injury to the optic nerve as the combination incorporating oxATP.
Introduction
Following neurotrauma, a series of metabolic and structural changes are propagated in initially undamaged tissue, associated with increased intracellular Ca 2+ , oxidative stress and apoptotic cell death of neurons and glia (Dong et al. 2009 ). Since the initial insult is often unavoidable, treatments for functional recovery after neurotrauma focus heavily on limiting this secondary damage (Doan et al. 2016) . However, despite extensive research, effective pharmacotherapeutic treatments for secondary degeneration following neurotrauma are limited . To successfully limit secondary degeneration following neurotrauma, it is important to test efficacy of treatments in appropriate animal models of injury. Partial optic nerve transection is an established and useful model for investigating secondary degeneration, where the dorsal optic nerve of adult rats is partially transected, allowing for spatial separation between the primary and subsequent secondary degeneration (Levkovitch-Verbin et al. 2003; Blair et al. 2005) . The model has been further characterised and employed to assess efficacy of pharmacotherapeutics for secondary degeneration, delivered directly to the injury site using osmotic mini-pumps (Fitzgerald et al. 2009a, b; Savigni et al. 2013; Doig et al. 2017) .
Secondary degeneration is characterised by a myriad of reactive metabolic pathways, including inflammation, excitotoxicity, mitochondrial dysfunction and oxidative stress, associated with structural deficits, dysmyelination and apoptotic cell death (Tymianski and Charles 1996; Dong et al. 2009; Maxwell 2013) . Ca 2+ overload is considered to be a major trigger for the toxic mechanisms of secondary degeneration (Farooqui et al. 2008) . Using the partial optic nerve transection model, we have previously demonstrated that a locally delivered combinatorial treatment strategy to limit excess Ca 2+ influx through voltage-gated calcium channels, P2X 7 receptors and Ca 2+ permeable AMPA receptors with lomerizine, oxATP and YM872, respectively, reduced myelin decompaction, preserved node/paranode structure and visual function (Savigni et al. 2013) . Acute outcomes indicated that early preservation of node/paranode structure and OPC numbers was associated with longer term preservation of visual function (Doig et al. 2017) .
Following mild traumatic brain injury, it is currently unclear as to whether there is a blood-brain barrier breach, with studies reporting varying degrees of compromise of blood-brain barrier integrity following injury (Deford et al. 2002; Tomkins et al. 2011; Zetterberg et al. 2013 ). Therefore, pharmacotherapies designed to treat all but the most severe cases of neurotrauma, need to be able to travel across the closed blood-brain barrier following systemic delivery. oxATP does not appear to be able to cross the blood-brain barrier (Peng et al. 2009 ). Thus, for clinical applicability of the lomerizine, oxATP and YM872 combination, oxATP needs to be substituted with a blood-brain barrier permeable P2X 7 receptor antagonist. Here we introduce an alternative P2X 7 receptor inhibitor Brilliant Blue G (BBG) to the combination. BBG has previously shown therapeutic effects following neurotrauma (Peng et al. 2009; Kimbler et al. 2012; Wang et al. 2015) , and importantly, can cross the closed blood-brain barrier (Wong et al. 2011) . This study compared the efficacy of the ion channel inhibitor combination of lomerizine + BBG + YM872 to a combination with lomerizine + oxATP + YM872 for limiting secondary degeneration and restoring function following partial optic nerve transection.
Methods

Animals and study design
Thirty-eight adult, female PVG rats were obtained from the Animal Resource Centre in Murdoch, Western Australia. The animals were housed under 12-h light/dark cycles with ad libitum access to food and water. All procedures were approved by the University of Western Australia Animal Ethics Committee (approval number RA3/100/1485) and were in accordance with the National Health and Medical Research Council (NHMRC) of Australia Code of Practice for use of Animals for Scientific Purposes. The animals were divided into four experimental groups, a sham-injured, vehicle-treated group (n = 8); an injured, vehicle-treated group (n = 10); an injured, lomerizine + oxATP + YM872-treated group (n = 10); and an injured, lomerizine + BBG + YM872-treated group (n = 10); with the sham group serving as an uninjured, vehicle-treated control.
Surgical procedures
Partial optic nerve transection (day 1) and left eyelid suturing (day 3) were performed as previously described (Fitzgerald et al. 2009a) , under ketamine (ketamil, 50 mg/kg, Troy Laboratories) and xylazine (Ilium Xylazil, 10 mg/kg, Troy Laboratories) anaesthesia administered intraperitoneally. In brief, for the partial transection surgery: the skin overlying the skull behind the right eye was incised. The optic nerve was accessed and the nerve parenchyma exposed by making a longitudinal cut in the sheath using fine iridectomy scissors. About 1 mm behind the right eye, the dorsal aspect of the optic nerve was partially lesioned to a depth of approximately 200 µm with a diamond radial keratotomy knife (Geuder); the depth determined by the protrusion of the blade beyond the surrounding guard. Sham injury included all procedures except the cut in the sheath and the partial optic nerve lesion. Surgical implantation of Alzet osmotic mini-pumps was performed as described (Savigni et al. 2013) . Immediately following surgery, subcutaneous injections of analgesia (2.8 mg/kg carprofen, Norbrook) and 1 mL sterile phosphate buffered saline (PBS) were administered.
Treatments
Lomerizine (30 mg/kg, LKT Labs © ) was orally administered in butter vehicle twice daily 8 h apart, until end of the experiment, commencing once animals were ambulatory following surgery as previously described (Fitzgerald et al. 2009a) . oxATP (1 mM), BBG (540 µM) and YM872 (240 µM) were delivered via osmotic mini-pump at 0.5µL/h in PBS vehicle. Concentrations employed for oxATP and YM872 were consistent with our previous studies where efficacy was demonstrated (Savigni et al. 2013) , and the BBG dose was chosen with reference to the literature describing efficacy of BBG and YM872 in related models (Takahashi et al. 2002; Diaz-Hernandez et al. 2012; Cervetto et al. 2013) . The sham-injured and partial optic nerve transection injured, vehicle-treated experimental groups both received PBS via osmotic mini-pump and butter orally, administered as described for the inhibitor-treated groups.
Behavioural assessment
On day 3, the animals were anaesthetised as described above and their uninjured left eyelids sutured shut. The optokinetic nystagmus assessment of visual function was performed on day 4 for all animals, in accordance with established procedures (Fitzgerald et al. 2010b ). Animals were videoed and the number of responses per unit time engaged in the task was determined by a single investigator blinded to animal identity. Note that due to a procedural error, n = 5 for the injured, vehicle-treated group. Responses were categorised as either smooth pursuits or fast resets. Smooth pursuits are characterised as an elongated head rotation tracking the stripes, and fast resets as a rapid, realigning head movement; both elements are an indication of visual ability of the animal (Abdeljalil et al. 2005) .
Tissue processing and immunohistochemistry
Immediately following behavioural assessment, rats were euthanised with pentobarbitone sodium (160 mg/kg, Delvet), transcardially perfused with 0.9% saline, followed by 4% paraformaldehyde (Sigma-Aldrich) in 0.1M PBS. Optic nerves were dissected and fixation continued overnight by immersion in 4% paraformaldehyde. Tissue was transferred into 15% sucrose (Chem Supply) in PBS, then cryosectioned in longitudinal orientation at a thickness of 14 µm and collected onto Superfrost Plus glass microscope slides. Immunohistochemistry was conducted in accordance with established procedures (Fitzgerald et al. 2010a ) using primary antibodies recognising: microglial activation markers Iba1 (1:500; Abcam, goat Ab5076) and ED1 (1:500; Merck Millipore, mouse MAB1435); oligodendroglial indicators oligodendrocyte transcription factor 2 (Olig2; 1:500; R&D Systems, goat AF2418) and platelet-derived growth factor alpha receptor (PDGFαR; 1:500; Abcam Ab96806); and for paranode and node of Ranvier structures Caspr (1:500; Abcam, rabbit Ab34151), and β-III tubulin (1:500; Merck Millipore, mouse MAB1637). Antibodies were diluted in PBS containing 0.2% Triton™ X-100 and 5% normal donkey serum. Secondary antibodies were Alexa Flour 488 or 555 (1:400; Thermo Fisher Scientific™), together with Hoechst 3342 (1:1000; Thermo Fisher Scientific™) diluted in PBS containing 0.2% Triton™ X-100. Finally, the sections were mounted and cover slipped using Fluoromount-G (Thermo Fisher Scientific).
Imaging and analysis
The ventral optic nerve directly below the site of injury was visualised, with one field of view from one section per animal imaged for each outcome measure. The slides were viewed using either a Nikon Ni-E confocal fluorescence microscope (Nikon Corporation) or a Nikon Eclipse Ti-inverted microscope. A series of 13 optical images were taken at 0.5 µm increments along the z axis, and deconvoluted using Nikon Elements AT software. Imaging for each outcome measure was performed in a single sitting with consistent capture settings. All image analysis was performed on Fiji image processing software (NIH) by a single investigator blinded to section identity. Due to poor fixation and tissue processing in a few animals, the number of animals per group analysed for immunohistochemistry outcomes were: sham-injured, vehicle-treated group (n = 8); injured, vehicle-treated group (n = 10); injured, lomerizine + oxATP + YM872-treated group (n = 8); and injured, lomerizine + BBG + YM872-treated group (n = 9).
Total numbers of Iba1+ resident reactive microglia, ED1+ activated microglia/macrophages, Olig2+ oligodendroglia and Olig2+/PDGFαR+ oligodendrocyte precursor cells (OPCs) were counted within a region of interest in a 20 × image of the ventral nerve directly beneath the primary injury site and expressed as the mean number of cells/mm 2 . For node/paranode analyses, a single 60 × z stack image per animal was divided into a 3 × 3 grid and all complexes with clearly defined Caspr immunostaining in a single randomly selected grid square assessed; at least 30 node/paranode complexes were analysed per animal. Outcome measures were the length of the paranodal gap, defined as the distance between two Caspr+ areas; paranode length, as defined by the length of Caspr+ areas; and the percentages of atypical nodal complexes, as previously described ).
Statistics
Results were analysed using IBM SPSS software. Outliers were detected using the Tukey's outlier detection model, whereby data that were greater than 1.5 interquartile ranges outside of the first and third quartiles were considered outliers and removed from the data set. No more than two outliers were removed per treatment group for each outcome measure, details are provided in figure legends. A single one-way ANOVA encompassing all four treatment groups were performed for each outcome measure. Normality was assumed, Levene's test was used to assess homogeneity of variances for each data set (α = 0.05). If Levene's test showed equal variance, the Tukey post hoc test was used; for unequal variance, the Games-Howell post hoc test was applied; both used p ≤ 0.05 to indicate statistical significance.
Results
Effects of ion channel inhibitor combinations on microglia and macrophages
Numbers of inflammatory cells in ventral optic nerve vulnerable to secondary degeneration were quantified using Iba1 for resident microglia, ED1 for infiltrating microglia/ macrophages, and colocalised Iba1+/ED1+ for infiltrating microglial cells (Wu et al. 2005) . The numbers of Iba1+ activated resident microglia were different in the various treatment groups (Fig. 1a, F = 3 .483, df = 3, p = 0.028), with the only statistically significant difference an increase in the number of Iba1+ cells when animals were treated with lomerizine + BBG + YM872 compared to the shaminjured, vehicle-treated group (p = 0.029). There was a trend towards increased Iba1+ cells with injury when comparing the injured, vehicle-treated group with the sham-injured, vehicle-treated group (p = 0.071). There was no significant difference between the two ion channel inhibitor combinations in the number of Iba1+ cells (p = 0.938).
In contrast, there was a significant difference in numbers of ED1+ infiltrating microglia/ macrophages (Fig. 1b , F = 2.5, df = 3, p = 0.079), with the numbers of the injured, vehicle-treated group significantly increased compared to sham-injured, vehicle-treated animals (p = 0.049). The number of ED1+ cells in the groups treated with either of the ion channel inhibitor combinations was not significantly different to either the injured, vehicle-treated group or the sham-injured, vehicle-treated group (p > 0.05). There was no significant difference between the two ion channel inhibitor combinations in the number of ED1+ cells (p = 0.994). Similarly, the number of Iba1+/ED1+ infiltrating microglial cells differed with experimental treatment (Fig. 1c , F = 2.912, df = 3, p = 0.041). A significant increase in the numbers of Iba1+/ED1+ cells was observed in the injured, vehicle-treated group compared to the sham-injured, vehicle-treated group (p = 0.024). Neither of the ion channel inhibitor treatment groups had significantly reduced numbers of Iba1+/ED1+ cells compared to the injured, vehicletreated group (p > 0.05). There was no significant difference between the two ion channel inhibitor combinations in the number of Iba1+/ED1+ cells (p = (Fig. 1d) .
Effects of ion channel inhibitor combinations on oligodendroglia
The densities of Olig2+ oligodendroglia were not different in any of the experimental groups (Fig. 2a, F = 2 .042, df = 3, p = 0.128); an example cell is shown (Fig. 2b) . However, when the analysis was refined to include immunoreactivity to PDGFαR, thereby detecting OPCs more specifically, there were significant differences between experimental groups (Fig. 2c, d , F = 4.681, df = 3, p = 0.008). As expected (Doig et al. 2017) , there was a significant decrease in the number of OPCs in the injured, vehicle-treated group compared to the sham-injured, vehicle-treated group (p = 0.007). However, neither ion channel inhibitor combination groups had significantly increased numbers of OPCs compared to the injured, vehicle-treated group (p > 0.05), and there was no significant difference between the two ion channel inhibitor combinations in the number of OPCs (p = 0.599).
Effects of ion channel inhibitor combinations on node/paranode complexes
Significant differences in the length of the paranode between experimental groups were observed (Fig. 3a , F = 52.445, df = 3, p = 0.0001). Partial optic nerve transection resulted in a significant increase in paranode length in the injured, vehicle-treated group compared to the shaminjured, vehicle-treated group (p = 0.0001), as expected from previous studies . While treatment with lomerizine + oxATP + YM872 reduced paranode Fig. 3 Effect of ion channel inhibitor combinations on node/paranode complexes. Paranode length (a), paranodal gap length (b) and percentage of atypical node/paranode complexes (c) from 30 nodal complexes per animal in the ventral optic nerve from sham-injured, vehicle-treated animals, injured, vehicle-treated animals, and ion channel inhibitor-treated animals 3 days after partial optic nerve transection. Graphs display min to max values, with the central line representing the median data point; N = 6-9 rats per group. Significant differences indicated by *p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001. Differences compared to the sham-injured, vehicle-treated group are indicated by *, similarly, differences compared to the injured, vehicle-treated group are indicated by #. d Representative image of two Caspr+ areas flanking a β-III tubulin+ area i.e. a typical nodal complex; scale bar 2 µm. e Representative image of one Caspr+ area flanking a β-III tubulin+ area denoting an atypical nodal complex/heminode; scale bar 2 µm length (p = 0.0001), paranodes remained longer than in the sham-injured, vehicle-treated group (p = 0.0001). Treatment with the lomerizine + BBG + YM872 combination also resulted in significantly reduced paranode lengths compared to the injured, vehicle-treated group (p = 0.0001), to levels significantly different to the shaminjured, vehicle-treated group (p = 0.001). Largely similar outcomes were observed when measuring the length of the paranodal gap, indicative of the length of the node of Ranvier (Fig. 3b, F = 20 .367, df = 3, p = 0.0001). There was no significant difference between the two ion channel inhibitor combinations in the length of the paranode (p = 0.084) or the paranodal gap (p = 0.122).
There were significant differences between experimental groups in the percentage of atypical nodal complexes (Fig. 3c-e, F = 374 .951, df = 3, p = 0.0001). Atypical nodal complexes were defined as either a heminode, characterised as a β-III tubulin+ area flanked by only one Caspr+ area (Fig. 3e) , or a single paranode, defined as a Caspr+ area not associated with a β-III tubulin + area . Injury resulted in an increase in the percentage of atypical nodal complexes in the injured, vehicle-treated group compared to the sham-injured, vehicle-treated group (p = 0.0001), which was significantly reduced by both lomerizine + oxATP + YM872 (p = 0.0001) and lomerizine + BBG + YM872 (p = 0.0001). However, both ion channel inhibitor combination groups still had significantly increased levels of atypical nodal complexes compared to the sham-injured, vehicle-treated group (p = 0.0001). There was no significant difference between the two ion channel inhibitor combinations in the number of atypical nodal complexes (p = 0.668).
Effects of ion channel inhibitor combinations on the optokinetic nystagmus reflex
The optokinetic nystagmus test of visual function revealed significant differences in the number of smooth pursuits and fast resets following injury and treatment ( Fig. 4a ; smooth pursuits F = 7.05, df = 3, p = 0.001; fast resets F = 7.656, df = 3, p = 0.001). Injury resulted in a significant decrease in the numbers of both smooth pursuits and fast resets by the injured, vehicle-treated group compared to the shaminjured, vehicle-treated group (p = 0.002, p = 0.001, respectively). Animals treated with lomerizine + oxATP + YM872 made significantly more smooth pursuits than the injured, vehicle-treated group (p = 0.035), but fewer fast resets than the sham-injured, vehicle-treated group (p = 0.006). Animals treated with lomerizine + BBG + YM872 made significantly more smooth pursuits (p = 0.002) and fast rests (p = 0.039) than the injured, vehicle-treated group; outcomes were not different from the sham-injured, vehicle-treated group (p = 0.992, p = 0.284, respectively). There was no significant difference between the two ion channel inhibitor combinations in the number of smooth pursuits (p = 0.422) or fast resets (p = 0.222).
To control for the length of the tracking motions, the time spent engaging in tracking behaviour was also assessed, giving similar outcomes (Fig. 4b, F = 11 .458, df = 3, p = 0.0001). Injury resulted in a significantly lower proportion of time spent engaging in smooth pursuits by the injured, vehicle-treated group compared to the shaminjured, vehicle-treated group (p = 0.0001). Animals treated with lomerizine + oxATP + YM872 spent more time tracking than the injured, vehicle group (p = 0.01), but still less time Fig. 4 Effects of injury and ion channel inhibitor combinations on the number of responses in the optokinetic nystagmus test of visual function. Total number of smooth pursuits and fast resets per minute engaged in the task (a) and proportion of time paying attention to task engaged in smooth pursuits (b) by sham-injured, vehicletreated animals; injured, vehicle-treated animals; or injured ion channel inhibitor-treated animals. Graphs display min to max values, with the central line representing the median data point; N = 5-10 rats per group. Significant differences are indicated by *p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001. Differences compared to the sham-injured, vehicletreated group are indicated by *, differences compared to the injured, vehicle-treated group are indicated by # 1 3 than the sham-injured, vehicle-treated group (p = 0.045). Animals treated with lomerizine + BBG + YM872 also spent significantly longer performing smooth pursuits than the injured, vehicle-treated group (p = 0.0001), and the time spent tracking was not significantly different to the shaminjured, vehicle-treated group (p = 0.161). There was no significant difference between the two ion channel inhibitor combinations in the time spent tracking (p = 0.601).
Discussion
The aim of this study was to determine if the combination of lomerizine + oxATP + YM872, shown to effectively limit functional loss associated with secondary degeneration of the optic nerve (Savigni et al. 2013) , would be as effective if oxATP was replaced with BBG, a more clinically applicable P2X 7 receptor inhibitor that can cross the closed blood-brain barrier. It was found that the lomerizine + BBG + YM872 combination was as effective, or marginally more effective at the tested concentrations, than the lomerizine + oxATP + YM872 combination, at preserving node/paranode structure and visual function when delivered locally. However, neither therapeutic combination affected numbers of microglia and macrophages, or the number of OPCs or oligodendrocytes. The data suggest an associative relationship between preservation of myelin structure and maintenance of visual function following injury.
The observed increase in nodal and paranodal lengths following partial optic nerve injury is in line with previous findings Doig et al. 2017) and is suggestive of myelin retraction and a breakdown of the paranodal junction (Arancibia-Carcamo and Attwell 2014). Increased P2X 7 receptor activation on the myelin sheath has also been associated with myelin degradation following injury, however the underlying cellular mechanisms remain unclear (Matute 2008) . The lomerizine + BBG + YM872 combination restored nodal and paranodal structure to dimensions slightly closer to the sham control group than the lomerizine + oxATP + YM872 combination. The lomerizine + BBG + YM872 combination was the only treatment to not be different to the sham control group for visual function. BBG is a more potent and selective antagonist of P2X 7 receptors than oxATP (Donnelly-Roberts and Jarvis 2007), which may explain this marginally greater efficacy of the BBG containing combination in preserving myelin structure and visual function compared to the control groups in the current study. However, titration of doses of these agents relative to their specific inhibitory concentrations for P2X 7 receptors is required to definitively compare efficacy of the two agents within the context of this treatment combination and injury model. We have previously established that locally delivered oxATP alone does not preserve node/ paranode structure nor visual function in the partial optic nerve transection model (Savigni et al. 2013 ). The addition of lomerizine and YM872 to the combination is required for full beneficial effects (Savigni et al. 2013) , emphasising that limiting excess Ca 2+ flux through voltage-gated calcium channels and Ca 2+ permeable AMPA receptors is also important.
Following injury to the CNS, there is a high influx of Ca 2+ into myelin via AMPA receptors (Fowler et al. 2003) , which results in increased Ca 2+ binding to the catalytic core of calpain, enhancing calpain activation (Croall and Demartino 1991; Khorchid and Ikura 2002 ). An increase in calpain activation can induce myelin degradation, via cleavage of myelin basic protein and myelin-associated glycoprotein (Banik et al. 1985; Shields et al. 1997; Fu et al. 2007) . Myelin degradation has been associated with paranodal loop eversion and sheath retraction and thus increased nodal and paranodal lengths (Ouyang et al. 2010) . Therefore, observed preservation of nodal and paranodal length by both ion channel combinations may be due to inhibition of this Ca 2+ -dependent calpain mechanism through the antagonistic activity of YM872 on AMPA receptors.
Furthermore, when the axolemma becomes exposed following myelin sheath retraction, and paranodal splitting, there is an increase in Ca 2+ entry into axons via sub-myelin L-type VGCCs, which are normally hidden underneath the myelin sheath (Zhang and David 2015) . This contributes to neuronal Ca 2+ overload, associated with oxidative stress, caspase-mediated apoptosis and decreased function (Annunziato et al. 2003) . Lomerizine-mediated inhibition of these sub-myelin VGCCs from beneath the sheath, together with exposure of fewer L-type VGCCs by prevention of the myelin retraction, may be a further therapeutic mechanism of the combinations of inhibitors.
Myelin structure is integral to the capacity of nerves to propagate action potentials, with the lengthening of the node associated with slower conduction velocities in a variety of pathologies (Howell et al. 2006; Reimer et al. 2011; Sun et al. 2012) . Abnormal myelination at a single internode can be sufficient to block neural signal transduction for an entire axon (Baumann and Pham-Dinh 2001) . Previous studies have also hypothesised that abnormalities in the node of Ranvier proteins, associated with increased nodal length, may result in decreased synchronicity of neuronal firing (Arancibia-Carcamo and Attwell 2014). Preservation of myelin integrity by the ion channel inhibitor combinations may be facilitating action potential propagation along axons, associated with preservation of function following injury.
However, in the current study, myelin structure and visual function were only partly preserved by the ion channel inhibitor treatments, which suggest some aspects of myelin breakdown following injury are mediated via alternative mechanisms of damage. One potential mechanism is immune cell-mediated depletion of OPCs. The current study found that following injury, there is a significant increase in infiltrating microglia and macrophages, but not resident microglial cells, indicative of an infiltrating immune response. However, treatment did not show a significant effect at ameliorating this infiltrating immune response. Following neurotrauma, inflammatory cells produce cytokines and chemokines, as well as reactive oxygen species, resulting in oxidative damage of surrounding tissue (Anderson 2002) . OPCs are especially vulnerable to oxidative stress and apoptosis following injury (Thorburne and Juurlink 1996; Giacci et al. 2018) , which may be why the combinations of ion channel inhibitors were unable to ameliorate the loss of OPCs in this study. OPCs are required for oligodendrogenesis and remyelination following injury (Mirron et al. 2011) . OPCs also contribute to the formation of myelin nodal structures (Butt et al. 2004 ). It may be that significantly preserving OPCs following injury, perhaps through preventing this infiltrating immune response, would be associated with a complete preservation of myelin structure and thus visual function. Furthermore, given previous studies have found an increased therapeutic effect of the lomerizine + oxATP + YM872 combination after 3 months of administration compared to 3 days (Savigni et al. 2013; Doig et al. 2017) , it may be that a longer duration of treatment would provide further improvements to these outcomes following injury.
This study showed that the combination of lomerizine + BBG + YM872, which has the potential to be delivered systemically following injury, shows promise for limiting secondary degeneration following neurotrauma, however further work remains to be done. While BBG is a highly selective P2X 7 receptor antagonist, it is 30-50 times more potent in rats than humans (Jiang et al. 2000) , which will necessitate careful titration of dosages before clinical translation will be feasible. Lomerizine is currently used in clinical practice (Hara et al. 1999) , YM872 is more soluble than other Ca 2+ permeable AMPA receptor inhibitors (Takahashi et al. 2002) and has been trialled in stroke with an acceptable safety profile (Labiche and Grotta 2004) and BBG has a no-observed-adverse-effect level of 8966 mg/kg per day in a mouse model of lifetime toxicity (Borzelleca et al. 1990 ). Nevertheless, while no adverse effects have been observed in our rodent model, the combination of three ion channel inhibitors will need to be careful assessed for toxicity in humans before a trial of efficacy following neurotrauma can be contemplated. Furthermore, given the clinical need for systemically administered drug delivery following neurotrauma, the efficacy of this blood-brain barrier permeable combination of lomerizine + BBG + YM872 needs to be tested when systemically delivered following injury.
